Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Gemcitabine Stories

2014-04-10 23:24:17

Mexican researchers say an alternative to the standard mesothelioma chemotherapy regimen can not only improve survival and quality of life, but can also save money. Raleigh, NC (PRWEB) April 10, 2014 Scientists in the Thoracic Oncology Unit at Mexico’s National Cancer Institute say continuous infusions of low-dose Gemzar (gemcitabine) with cisplatin appear to be a safe and effective alternative to standard mesothelioma chemotherapy. Click here to read about the new study on the...

2014-04-04 08:25:23

SAN DIEGO, April 4, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee (DMC), it is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer. The DMC is assessing clinical data that indicates a possible difference in the thromboembolic event rate between the...

2014-04-03 12:29:26

HAIFA, Israel, April 3, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that new, pre-clinical data demonstrating the anti-tumor effects of NovoTTF(TM) Therapy will be presented at the 2014 American Association for Cancer Research (AACR) in San Diego (April 5-9, 2014). The new study results show that ovarian cancer cells treated with Tumor Treating Fields (TTFields) exhibit abnormal chromosomal separation during cell division, reducing the viability of...

2014-03-27 12:30:55

A St. Jude Children's Research Hospital-led study identified two adult cancer drugs with potential to improve treatment of a high-risk childhood brain tumor; the drugs are now part of a pediatric clinical trial MEMPHIS, Tenn., March 27, 2014 /PRNewswire-USNewswire/ -- The quest to improve survival of children with a high-risk brain tumor has led St. Jude Children's Research Hospital investigators to two drugs already used to treat adults with breast, pancreatic, lung and other...

2014-03-24 23:24:12

Japanese researchers say the drug Alimta (pemetrexed) in combination with cisplatin should remain the top first-line treatment for malignant pleural mesothelioma. Raleigh, NC (PRWEB) March 24, 2014 Japanese researchers say the drug Alimta (pemetrexed) in combination with cisplatin should remain the top first-line treatment for malignant pleural mesothelioma. Their findings have just been posted by Surviving Mesothelioma at...

2014-03-18 08:32:43

-- ABRAXANE plus gemcitabine approved by the TGA for the first-line treatment of metastatic pancreatic cancer MELBOURNE, Australia, March 18, 2014 /PRNewswire/ -- Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE(®) (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer. The TGA approved...

2014-02-27 04:20:49

- Published Final Guidance Recommending PIXUVRI as Cost Effective and Provides Patients with Aggressive B-cell Non-Hodgkin Lymphoma (NHL) Greater Access to Only Approved Therapy - SEATTLE, Feb. 27, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the UK, has published...

2014-01-24 08:24:33

HAIFA, Israel, Jan. 24, 2014 /PRNewswire/ -- Novocure announced today that the first patient has enrolled in the EF-20 Study, an open label, pilot clinical trial of NovoTTF Therapy plus gemcitabine as first-line therapy for patients with locally advanced and metastatic pancreatic adenocarcinoma. NovoTTF Therapy is an anti-mitotic treatment delivered continuously with a wearable, home-use medical device. "The EF-20 study builds on extensive preclinical research demonstrating the...

2014-01-17 20:21:56

MELBOURNE, Australia, Jan. 17, 2014 /PRNewswire/ -- -- Study shows ABRAXANE plus gemcitabine combination therapy further extends overall survival benefit -- First Phase III trial in metastatic pancreatic cancer to report three year survival rates[1] -- New standard of care for patients with metastatic pancreatic cancer A leading breast cancer drug, ABRAXANE(®)( )(nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for...

2014-01-13 04:20:46

SEATTLE, Jan. 13, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that it has reached an agreement with Novartis to reacquire rights to two anti-cancer compounds -- pixantrone (PIXUVRI(®)) and paclitaxel poliglumex (Opaxio(TM)). Under the terms of the previous agreement, CTI has been responsible for development and commercialization activities and expenses for both compounds to date. Upon the effective date of termination, CTI will regain...